BeSpoke Decision Support
Research type
Research Study
Full title
Building and Evaluating a Stratified Prostate Cancer pathway (BeSpoke): the impact of BeSpoke Decision Support in patients with newly diagnosed localised prostate cancer – a single-blind randomised controlled trial with mixed method analysis
IRAS ID
347220
Contact name
Caroline Moore
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106/2024/10/50 , Data Protection Number
Duration of Study in the UK
2 years, 9 months, 1 days
Research summary
Around 55 000 men are diagnosed with prostate cancer in the UK every year, and around 12 000 men die of prostate cancer. We are carrying out a multi-site trial, evaluating the impact of the new BeSpoke Decision Support tool on assisting men with newly diagnosed localised prostate cancer, decide on their treatment path.
We will conduct a randomised controlled, single blind clinical trial comparing the BeSpoke DS, alongside aided consultations with current standard of care counselling. The aim of decision support is to assist the patient in making a well-informed decision which reflects their personal values, minimising decisional conflict and decision regret.
A parallel qualitative study will take place focusing on evaluating patients’ and clinicians’ perspective of the decision-making process and tools used for improvement. A mixed qualitative and quantitative implementation study will be carried out in order to assess the feasibility of introducing the tool in the wider NHS clinical practice.
REC name
London - Fulham Research Ethics Committee
REC reference
25/LO/0394
Date of REC Opinion
4 Jul 2025
REC opinion
Further Information Favourable Opinion